These findings suggest that clone size at PNH onset may serve as a prognostic factor for disease burden and MAVEs/TEs, aiding in clinical decision-making about treatment initiation or maintenance.

If you have a loved one with paroxysmal nocturnal hemoglobinuria (PNH), you know firsthand how challenging it can be to live with this disease. You may not think of yourself as a caretaker.